Education
About Us
Working with TipRanks
Follow Us
Supernus Pharmaceuticals (SUPN)
NASDAQ:SUPN
SUPN Stock Chart & Stats
$48.75
$0.29(0.76%)
At close: 4:00 PM EST
$48.75
$0.29(0.76%)
Day’s Range― - ―
52-Week Range$29.16 - $57.65
Previous CloseN/A
Volume41.90K
Average Volume (3M)883.24K
Market Cap
$2.77B
Enterprise Value$2.46B
Total Cash (Recent Filing)$281.16M
Total Debt (Recent Filing)$31.42M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Mar 03, 2026EPS Estimate
0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.00
Shares Outstanding57,339,350
10 Day Avg. Volume602,214
30 Day Avg. Volume883,241
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.92
Price to Sales (P/S)3.01
P/FCF Ratio11.64
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue3.61
Enterprise Value/Gross Profit4.29
Enterprise Value/Ebitda41.12
Forecast
1Y Price Target
$60.50Price Target Upside24.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)2.16
Revenue Forecast (FY)$702.59M
Bulls Say, Bears Say
Bulls Say
Pipeline DevelopmentSupernus is advancing its clinical pipeline with new studies for depression and epilepsy treatments, indicating active development and future growth potential.
Product GrowthQelbree's non-stimulant ADHD therapy is considered a significant engine of organic growth due to its differentiated profile and ability to capture market share.
Synergies And IntegrationThe integration of the Sage acquisition is proceeding better than expected, with significant reductions in SG&A expenses, and Supernus is confident in achieving up to $200 million in annualized synergies.
Bears Say
Commercial Uptake RisksThe primary risk to the investment thesis is slower-than-expected commercial uptake for Qelbree and Onapgo, as well as earlier than expected generic competitor launch.
Supply ConstraintsThe company is facing supply constraints for Onapgo, affecting its stock availability, which could impact sales.
Supernus Pharmaceuticals News
SUPN FAQ
What was Supernus Pharmaceuticals’s price range in the past 12 months?
Supernus Pharmaceuticals lowest stock price was $29.16 and its highest was $57.65 in the past 12 months.
What is Supernus Pharmaceuticals’s market cap?
Supernus Pharmaceuticals’s market cap is $2.77B.
When is Supernus Pharmaceuticals’s upcoming earnings report date?
Supernus Pharmaceuticals’s upcoming earnings report date is Mar 03, 2026 which is in 75 days.
How were Supernus Pharmaceuticals’s earnings last quarter?
Supernus Pharmaceuticals released its earnings results on Nov 04, 2025. The company reported $1.005 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.415.
Is Supernus Pharmaceuticals overvalued?
According to Wall Street analysts Supernus Pharmaceuticals’s price is currently Undervalued.
Does Supernus Pharmaceuticals pay dividends?
Supernus Pharmaceuticals does not currently pay dividends.
What is Supernus Pharmaceuticals’s EPS estimate?
Supernus Pharmaceuticals’s EPS estimate is 0.39.
How many shares outstanding does Supernus Pharmaceuticals have?
Supernus Pharmaceuticals has 57,339,350 shares outstanding.
What happened to Supernus Pharmaceuticals’s price movement after its last earnings report?
Supernus Pharmaceuticals reported an EPS of $1.005 in its last earnings report, beating expectations of $0.59. Following the earnings report the stock price went down -17.351%.
Which hedge fund is a major shareholder of Supernus Pharmaceuticals?
Currently, no hedge funds are holding shares in SUPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Supernus Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$60.50 (24.10% Upside)
$60.50 (24.10% Upside)
Blogger Sentiment
Bullish
SUPN Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 464.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.5%
Last 30 Days ▲ 21.3%
Last 30 Days ▲ 21.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.41%
12-Months-Change
Fundamentals
Return on Equity
-1.86%
Trailing 12-Months
Asset Growth
5.74%
Trailing 12-Months
Company Description
Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system (CNS) disorders. The company primarily targets conditions such as epilepsy and attention-deficit hyperactivity disorder (ADHD) with a portfolio of proprietary products that include marketed drugs like Oxtellar XR and Trokendi XR. Supernus operates in the biopharmaceutical sector, leveraging its expertise in drug formulation and development to enhance treatment options for patients.
SUPN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong growth in key products and an optimistic financial outlook overshadowed by significant operating losses and supply constraints for Onapgo. The company is addressing these challenges while maintaining a focus on future growth opportunities.View all SUPN earnings summariesSUPN Stock 12 Month Forecast
Average Price Target
$60.50
▲(24.10% Upside)
Technical Analysis
Avadel Pharmaceuticals
―
Perrigo Company
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Alvotech
―
Ownership Overview
4.29% Insiders
31.80% Mutual Funds
24.11% Other Institutional Investors
12.94% Public Companies and
Individual Investors